pyrazole has been researched along with Disease Models, Animal in 14 studies
1H-pyrazole : The 1H-tautomer of pyrazole.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to discover and develop drug-like anti-inflammatory agents against arthritis, based on "Hit" we found earlier and to overcome drawbacks of toxicity, twelve series of total 89 novel pyrimidine, pyrazolo[4,3-d]pyrimidine and thieno[3,2-d]pyrimidine derivatives were designed, synthesized and screened for their anti-inflammatory activity against NO and toxicity for normal liver cells (LO2)." | 8.02 | Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis. ( Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL, 2021) |
| " Ablation of TRPC3 lessens pilocarpine-induced seizures in mice, suggesting that TRPC3 inhibition might represent a novel antiseizure strategy." | 4.12 | Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects. ( Boda, VK; Hou, R; Jiang, J; Li, L; Li, W; Nagib, MM; Wu, Z; Yasmen, N; Yu, Y; Zhang, S, 2022) |
| "In order to discover and develop drug-like anti-inflammatory agents against arthritis, based on "Hit" we found earlier and to overcome drawbacks of toxicity, twelve series of total 89 novel pyrimidine, pyrazolo[4,3-d]pyrimidine and thieno[3,2-d]pyrimidine derivatives were designed, synthesized and screened for their anti-inflammatory activity against NO and toxicity for normal liver cells (LO2)." | 4.02 | Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis. ( Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL, 2021) |
| "Compound 10 exhibited diabetic neuropathic pain-alleviating effects in a streptozotocin-induced peripheral diabetic neuropathy (PDN) model." | 1.46 | Synthesis and diabetic neuropathic pain-alleviating effects of 2N-(pyrazol-3-yl)methylbenzo[d]isothiazole-1,1-dioxide derivatives. ( Choi, YJ; Hong, JR; Keum, G; Nam, G, 2017) |
| "However, CYP2A5 expression during nonalcoholic fatty liver disease (NAFLD) is still unknown." | 1.39 | Expression of cytochrome P450 2A5 in a C57BL/6J mouse model of nonalcoholic fatty liver disease. ( Cao, Y; Guo, G; Li, R; Liu, F; Wang, Y; Zhang, X, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Mironov, ME | 1 |
| Borisov, SA | 1 |
| Rybalova, TV | 1 |
| Baev, DS | 1 |
| Tolstikova, TG | 1 |
| Shults, EE | 1 |
| Nagib, MM | 1 |
| Zhang, S | 1 |
| Yasmen, N | 1 |
| Li, L | 1 |
| Hou, R | 1 |
| Yu, Y | 1 |
| Boda, VK | 1 |
| Wu, Z | 1 |
| Li, W | 1 |
| Jiang, J | 2 |
| Reddy, VG | 1 |
| Reddy, TS | 1 |
| Jadala, C | 1 |
| Reddy, MS | 1 |
| Sultana, F | 1 |
| Akunuri, R | 1 |
| Bhargava, SK | 1 |
| Wlodkowic, D | 1 |
| Srihari, P | 1 |
| Kamal, A | 1 |
| Chen, LZ | 1 |
| Shu, HY | 1 |
| Wu, J | 1 |
| Yu, YL | 1 |
| Ma, D | 1 |
| Huang, X | 1 |
| Liu, MM | 1 |
| Liu, XH | 1 |
| Shi, JB | 1 |
| Hong, JR | 1 |
| Choi, YJ | 1 |
| Keum, G | 1 |
| Nam, G | 1 |
| Li, R | 1 |
| Guo, G | 1 |
| Cao, Y | 1 |
| Wang, Y | 1 |
| Liu, F | 1 |
| Zhang, X | 1 |
| Zhang, H | 1 |
| Zhu, P | 1 |
| Liu, J | 1 |
| Lin, Y | 1 |
| Yao, H | 1 |
| Ye, W | 1 |
| Wu, X | 1 |
| Xu, J | 1 |
| Chauhan, V | 1 |
| Chauhan, A | 1 |
| Grant, S | 1 |
| Tran, P | 1 |
| Zhang, Q | 1 |
| Zou, A | 1 |
| Dinh, D | 1 |
| Jensen, J | 1 |
| Zhou, S | 1 |
| Kang, X | 1 |
| Zachwieja, J | 1 |
| Lippincott, J | 1 |
| Liu, K | 1 |
| Johnson, SL | 1 |
| Scales, S | 1 |
| Yin, C | 1 |
| Nukui, S | 1 |
| Stoner, C | 1 |
| Prasanna, G | 1 |
| Lafontaine, J | 1 |
| Wells, P | 1 |
| Li, H | 1 |
| El-Sayed, MA | 1 |
| Abdel-Aziz, NI | 1 |
| Abdel-Aziz, AA | 1 |
| El-Azab, AS | 1 |
| Asiri, YA | 1 |
| Eltahir, KE | 1 |
| Rikimaru, K | 1 |
| Wakabayashi, T | 1 |
| Abe, H | 1 |
| Imoto, H | 1 |
| Maekawa, T | 1 |
| Ujikawa, O | 1 |
| Murase, K | 1 |
| Matsuo, T | 1 |
| Matsumoto, M | 1 |
| Nomura, C | 1 |
| Tsuge, H | 1 |
| Arimura, N | 1 |
| Kawakami, K | 1 |
| Sakamoto, J | 1 |
| Funami, M | 1 |
| Mol, CD | 1 |
| Snell, GP | 1 |
| Bragstad, KA | 1 |
| Sang, BC | 1 |
| Dougan, DR | 1 |
| Tanaka, T | 1 |
| Katayama, N | 1 |
| Horiguchi, Y | 1 |
| Momose, Y | 1 |
| Xiong, Y | 1 |
| Guo, J | 1 |
| Candelore, MR | 1 |
| Liang, R | 1 |
| Miller, C | 1 |
| Dallas-Yang, Q | 1 |
| Jiang, G | 1 |
| McCann, PE | 1 |
| Qureshi, SA | 1 |
| Tong, X | 1 |
| Xu, SS | 1 |
| Shang, J | 1 |
| Vincent, SH | 1 |
| Tota, LM | 1 |
| Wright, MJ | 1 |
| Yang, X | 1 |
| Zhang, BB | 1 |
| Tata, JR | 1 |
| Parmee, ER | 1 |
| Lu, Y | 1 |
| Cederbaum, AI | 1 |
| Nichols, KD | 1 |
| Kirby, GM | 1 |
14 other studies available for pyrazole and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis of Anti-Inflammatory Spirostene-Pyrazole Conjugates by a Consecutive Multicomponent Reaction of Diosgenin with Oxalyl Chloride, Arylalkynes and Hydrazines or Hydrazones.
Topics: Animals; Anti-Inflammatory Agents; Chemistry Techniques, Synthetic; Chlorides; Combinatorial Chemist | 2021 |
Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects.
Topics: Animals; Disease Models, Animal; Mice; Pentylenetetrazole; Pilocarpine; Pyrazoles; Seizures | 2022 |
Pyrazolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Benzothiazoles; Cell Cycle; Cell | 2019 |
Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.
Topics: Administration, Oral; Animals; Arthritis; Cells, Cultured; Dimerization; Disease Models, Animal; Dos | 2021 |
Synthesis and diabetic neuropathic pain-alleviating effects of 2N-(pyrazol-3-yl)methylbenzo[d]isothiazole-1,1-dioxide derivatives.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, T-Type; Diabetic Neuropathies; Disease Models, | 2017 |
Expression of cytochrome P450 2A5 in a C57BL/6J mouse model of nonalcoholic fatty liver disease.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2A6; Cytochrome P450 Family 2; Diet, Hig | 2013 |
Synthesis, in vitro and in vivo antitumor activity of pyrazole-fused 23-hydroxybetulinic acid derivatives.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, | 2015 |
Effects of methylmercury and alcohol exposure in Drosophila melanogaster: Potential risks in neurodevelopmental disorders.
Topics: Administration, Oral; Alcohol Dehydrogenase; Analysis of Variance; Animals; Central Nervous System D | 2016 |
Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model.
Topics: Administration, Oral; Animals; Cattle; Cell Line; Diabetes Complications; Disease Models, Animal; Dr | 2010 |
Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.
Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Computer Simulation; Cyclooxygenase 1; Cyclooxygen | 2011 |
A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides.
Topics: Animals; Binding Sites; Carboxylic Acids; Computer Simulation; Diabetes Mellitus, Experimental; Dise | 2012 |
Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.
Topics: Animals; Area Under Curve; beta-Alanine; Blood Glucose; CHO Cells; Cricetinae; Cricetulus; Diabetes | 2012 |
Enhancement by pyrazole of lipopolysaccharide-induced liver injury in mice: role of cytochrome P450 2E1 and 2A5.
Topics: Alcohol Dehydrogenase; Animals; Aryl Hydrocarbon Hydroxylases; Blotting, Western; Chemical and Drug | 2006 |
Expression of cytochrome P450 2A5 in a glucose-6-phosphate dehydrogenase-deficient mouse model of oxidative stress.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Aryl Hydrocarbon Hydroxylases; Catalase; Cytochr | 2008 |